Please provide your email address to receive an email when new articles are posted on . In TEMPO-1, fixed 5 mg and 15 mg doses of tavapadon improved outcomes in patients with Parkinson’s disease.
Tavapadon will enter a competitive but commercially attractive market after a likely regulatory submission following post-hoc data.
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with ...
Tavapadon may delay levodopa use in early Parkinson’s and help stabilize dosing in the later stages of the disease, with most ...
On Thursday, AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson’s disease. Tavapadon is an investigational D1/D5 ...
An experimental Parkinson’s disease drug on its way to AbbVie as part of an $8.7 billion acquisition has met the goals of a pivotal study, setting up the pharmaceutical giant with a drug prospect that ...
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results